What Farmacon Global does

Farmacon Global is a private, founder-led strategic contract research organization (CRO) of medical consultants founded circa 2009 and headquartered in West Palm Beach, Florida, with a fully distributed remote operating model. The company specializes in accelerating clinical trial execution and supporting market access for pharmaceutical and biotechnology sponsors across Latin America and other emerging markets, with therapeutic expertise in rare diseases, immunology, infectious diseases, oncology, and vaccines. Services span the full drug development lifecycle — from strategy and protocol planning, through regulatory affairs and clinical trial execution (site identification, enrollment acceleration, medical monitoring, pharmacovigilance), to market access and post-trial advisory — delivered through a hybrid model combining in-house medical experts with a network of on-the-ground local CRO, regulatory, and laboratory partners across Brazil, Argentina, Mexico, Colombia, Peru, and Central America.

Farmacon's product portfolio consists of core CRO consulting and market access services, supplemented by the Farmacon Academy investigator training program, the Rare DIEM Alliance community platform (co-organized with UC San Diego Extended Studies), the annual Rare DIEM virtual summit, and the LINK corporate social responsibility program (free genetic testing for rare disease patients via Mendelics Lab). Technology infrastructure is cloud-based (Google Workspace with enforced 2FA and zero-trust data policies) and integrated with third-party eClinical partners including Jeeva Informatics and Validcare, but the company does not maintain a proprietary software platform — its differentiation lies in network assets, regulatory expertise, and human capital rather than software IP.

Revenue is generated through project-based professional services engagements priced on a quote-by-quote basis with pharmaceutical and biotech sponsors, distributed primarily via direct enterprise sales with leadership involvement. Notable client engagements include 19,000-patient enrollment across 32 sites in 5 countries for a Phase III COVID-19 vaccine trial, top-recruiter status for Mirum Pharmaceuticals' MARCH-PFIC Phase 3 study, and 100% patient retention in a Phase 3 Hunter's disease trial in Mexico. The company is bootstrapped with no disclosed external funding and operates with a small team spanning the U.S. and Latin America.

Name

Farmacon Global

Legal name

Farmacon Global

Website

https://farmaconglobal.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Farmacon Global is a strategic contract research organization of medical consultants accelerating clinical trials and market access for pharmaceutical and biotech sponsors across Latin America and other emerging markets, with specialization in rare diseases, oncology, and vaccines.

Ownership category

akta.pro rank

Product category

Clinical Research Services (Contract Research Organization)

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Clinical research services
• Contract research organization
• Market access consulting
• Rare disease trials
• Latin America clinical trials

Headquarters

HQ city

West Palm Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

1. Clinical Research Services: Farmacon Global provides integrated clinical research services throughout the entire drug development lifecycle, including strategy and planning, regulatory affairs, clinical trial execution, site network management, enrollment acceleration, medical monitoring, pharmacovigilance, and market access support. Services are delivered through a combination of in-house medical experts and a network of on-the-ground local partners. As a strategic CRO, the company generates revenue through project-based consulting and service fees, likely structured as professional services engagements with pharmaceutical and biotech sponsors.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Farmacon Global provides strategic clinical research consulting and market access services to pharmaceutical and biotech sponsors seeking to conduct clinical trials and commercialize therapies in Latin America and other emerging markets. Its offering spans the full drug development lifecycle — strategy and planning, regulatory affairs, site network management, patient enrollment acceleration, medical monitoring, pharmacovigilance, compassionate use facilitation, and commercialization support — delivered through a remote team of medical consultants and a network of on-the-ground KOLs, local CRO partners, laboratories, and technology providers. Supplementary offerings include the Farmacon Academy investigator training program and the Rare DIEM Alliance rare disease community platform.

Product overview

Farmacon Global is a strategic CRO of medical consultants offering integrated solutions for clinical research and market access in Latin America and emerging markets. The portfolio consists of core consulting services (clinical research consulting and market access services), supplemented by specialized programs including Farmacon Academy (clinical research training), Rare DIEM Alliance (rare disease research collaboration platform), and the annual Rare DIEM Virtual Summit. Additional services include diversity action plans, pharmacovigilance, compassionate use facilitation, and professional training programs (CRO, CRA, Medical Monitor, MSL training). The company operates as a service-based business rather than a software platform, providing expert medical consulting, regulatory navigation, site network intelligence, and medical training throughout the clinical trial development lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Consulting Services Strategic consulting services for clinical trial planning and execution across the full drug development lifecycle in Latin America, including protocol development, site identification, patient enrollment acceleration, medical monitoring, site network management, and regulatory support. Targeted at pharmaceutical and biotech sponsors seeking to run clinical trials in emerging markets.
• Market Access Services Comprehensive market access solutions for pharmaceutical and biotech companies entering Latin American markets, including regulatory navigation across ANVISA, COFEPRIS, INVIMA, and ANMAT, compliance support, and commercialization strategy. Supports sponsors from regulatory approval through successful commercialization in LATAM markets.
• Farmacon Academy Clinical research training program that teaches doctors and healthcare workers to become qualified independent research investigators, coordinators, and consultants through a virtual curriculum and in-person training covering protocol development, GCP, bioethics, and clinical trial operations. Graduates are certified as Farmacon Academy-certified investigators. Targeted at investigators and site staff in Latin America.
• Rare DIEM Alliance Collaborative platform that fosters clinical research initiatives for rare diseases in emerging markets, connecting researchers, healthcare professionals, patient advocacy groups, and policymakers in Latin America through quarterly assemblies and ongoing community engagement. Provides a network for patient advocacy outreach, investigator engagement, and patient advocacy group identification for sponsors.
• Rare DIEM Virtual Summit Annual virtual conference co-organized with UC San Diego Division of Extended Studies focused on rare disease research and clinical trial opportunities in Latin America, bringing together biopharma, the medical community, patient advocacy groups, government representatives, and investigators through keynote presentations, panel discussions, Q&A, breakout rooms, and simultaneous translation.
• Diversity Action Plan Services Services focused on addressing FDA-recommended Diversity Action Plans for clinical trials, leveraging Latin America and other diverse regions to support inclusive trial enrollment. Designed for pharmaceutical and biotech sponsors seeking to meet FDA diversity guidance.
• Pharmacovigilance Services Post-trial and during-trial pharmacovigilance services for safeguarding patient well-being through rigorous monitoring and adverse event tracking across LATAM clinical trials.
• Compassionate Use Facilitation Service facilitating access to investigational treatments for patients outside of clinical trials who have exhausted standard therapeutic options, particularly in Latin America.
• CRO Training Services Training services for Contract Research Organizations to elevate their capabilities in clinical trial operations across LATAM, covering operational best practices and local regulatory landscape knowledge.
• CRA Monitor Training Training programs for Clinical Research Associates to develop skilled monitors for effective trial oversight in LATAM clinical trials.
• Medical Monitor Training Training services to equip medical monitors with skills for maintaining high medical standards in clinical trials across LATAM regions.
• MSL Training Training programs for Medical Science Liaisons to enable impactful engagement with healthcare professionals across Latin America.

Quantifiable outcome

• Saved 6 months of start-up time for a Rare Kidney Disease project in Brazil and Argentina by enrolling the largest number of patients.
• +6 more outcomes

Named customers23 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered minor and core.

• NutreominorStrategic or Co-development Partner · 1 January 2026Farmacon Global is partnering with Nutreo to bring the Vitamix micronutrient powder product to Latin American markets. Vitamix is a 1g sachet containing 10 vitamins and 5 minerals formulated to address micronutrient deficiencies identified as drivers of cognitive decline in the region. This partnership extends Farmacon's market access and LATAM health landscape expertise to the nutraceutical sector.
• Jeeva Informatics SolutionscoreTechnology or Integration · 26 October 2022Farmacon Global partnered with Jeeva Informatics Solutions, an eClinical cloud platform, to enable faster patient recruitment and better patient retention in clinical studies, particularly rare disease trials. The partnership combines Farmacon's LATAM on-the-ground expertise with Jeeva's eClinical Cloud platform to accelerate patient enrollment by 3x and improve trial flexibility in the post-pandemic environment. Sponsors working with both companies benefit from time and cost performance improvements in clinical trial execution.
• UC San Diego Division of Extended StudiescoreStrategic or Co-development Partner · 8 July 2022Farmacon Global and UC San Diego Division of Extended Studies co-organize the annual Rare DIEM (Rare Disease in Emerging Markets) virtual conference, bringing together experts from biopharma, the medical community, academia, patient advocacy groups, and government representatives. UCSD provides academic credibility and perspective, while Farmacon contributes industry expertise and LATAM network connections. The partnership includes the formation of a Rare DIEM Alliance advisory board and ongoing collaboration for clinical research education.
• ValidcarecoreTechnology or Integration · 3 February 2022Farmacon Global partnered with Validcare to offer empirical results from more facile connections with trial participants through e-CRF, e-diaries, and efficient real-world evidence (RWE) data. Validcare provides a decade of experience powering clinical trials and value-based care models spanning pharma, med device, and supplement market segments, offering best practices in streamlining research for regulatory compliant, life-improving products. The partnership enables quick evaluation of ROI for enrollment acceleration activities and provides measurable outcomes against industry benchmarks.
• Americas Health FoundationcoreStrategic or Co-development PartnerAmericas Health Foundation serves as a bridge between industry and governments, creating multi-stakeholder collaboration for the future of healthcare in Latin America. Farmacon Global partners with the foundation to promote increased access to quality healthcare and treatments throughout the Americas, with Dick Salvatierra (Founder and President) contributing expertise on federal government contracting, business development, and rare disease policy across Mexico, Ecuador, and Honduras. The foundation also participates in the Rare DIEM Alliance.
• Mendelics LabcoreTechnology or IntegrationMendelics Lab, described as the first and largest Brazilian laboratory specializing in genetic diagnostic tests for rare diseases and cancer through Next Generation Sequencing (NGS), partnered with Farmacon Global for the LINK corporate social responsibility program providing free genetic testing for rare disease patients in Latin America. The partnership also involves collaboration on clinical trials, including a study for PFIC (Progressive Familial Intrahepatic Cholestasis) diagnosis. Mendelics is a sponsor of the Rare DIEM Alliance.
• Mirum PharmaceuticalscoreStrategic or Co-development PartnerMirum Pharmaceuticals is a sponsor of the Rare DIEM virtual conference and has engaged Farmacon Global for clinical trial support. Farmacon contributed significantly to Mirum's MARCH-PFIC Phase 3 clinical trial, with Latin America through Farmacon becoming the top-recruiting region. Mirum is a Champion of Diversity sponsor of the Rare DIEM Alliance.
• Local CRO Partners (Latin America)coreChannel Partner/ Reseller/ DistributorFarmacon Global has cultivated strategic partnerships with local CROs across key countries in Latin and Central America. These partnerships navigate the complexities of diverse regulatory landscapes, ensure comprehensive understanding of local regulations, expedite approvals, and guarantee successful compliance in each targeted market. The partnerships blend Farmacon's global expertise with local insights of trusted partners for seamless execution of clinical trials and market access projects.
• Local Regulatory Partners (Latin America)coreChannel Partner/ Reseller/ DistributorStrategic regulatory partners across Latin and Central America support Farmacon Global in navigating country-specific regulatory frameworks, facilitating expedited approvals, and ensuring compliance with ANVISA, COFEPRIS, INVIMA, ANMAT, and other regional regulatory authorities.
• Casa HunterminorStrategic or Co-development PartnerCasa Hunter, founded by Antoine Daher in Brazil, is a rare disease advocacy organization that has led in creating government policy on rare disease, positively affecting patients and families. Daher participates in the Rare DIEM conference as a panelist, contributing expertise on overcoming challenges of market access for rare disease treatments and navigating government policy in Brazil.
• Travere TherapeuticsminorStrategic or Co-development PartnerTravere Therapeutics has been a sponsor of the Rare Diem conference and has utilized Farmacon Global's services for clinical trial support in Latin America. Travere participated as a conference sponsor representing the rare disease pharmaceutical sector.
• KOL and Investigator NetworkcoreStrategic or Co-development PartnerFarmacon Global has an extensive network of Key Opinion Leaders (KOLs), principal investigators, and on-the-ground medical experts across Latin America including Brazil, Argentina, Mexico, Colombia, Peru, Panama, Cuba, Venezuela, Paraguay, Chile, and Central America. These relationships enable culturally sensitive insights, site identification, patient enrollment, and medical monitoring for clinical trials.
• Patient Advocacy Groups (PAGs)minorStrategic or Co-development PartnerFarmacon Global works with patient advocacy groups across Latin America to facilitate PAG identification, outreach, and engagement for clinical trials. PAGs include organizations such as Casa Hunter (Brazil), ENLACE (Mexico, Duchenne & Becker Muscular Dystrophy), FUNCOLEHF (Colombia), and others that help connect sponsors with rare disease patient communities.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Syneos Health: Global biopharma solutions organization offering clinical development and commercial services. Overlaps with Farmacon's clinical-to-market-access positioning, though at significantly larger scale with broader geographic footprint.
• IQVIA: Largest global CRO with established LATAM operations across Brazil, Argentina, Mexico, and other markets. Overlaps significantly with Farmacon's service portfolio but operates at massive scale with proprietary technology platforms.
• Labcorp Drug Development (formerly Covance): Large global CRO with integrated central laboratory and clinical development services, including LATAM presence. Competes for enterprise pharma sponsors seeking full-service capabilities with embedded diagnostics.
• Parexel International: Major global CRO with broad LATAM clinical trial capabilities and significant rare disease experience. Competes with Farmacon for enterprise pharma sponsors but offers broader service portfolio including commercialization support.

Direct peers

• Medpace: Mid-size global CRO specializing in therapeutic areas including oncology, rare diseases, and immunology. Comparable in its full-service clinical development model and therapeutic specialty focus, though operating at significantly larger scale.
• Clinipace Worldwide: Mid-size global CRO with strong LATAM presence and therapeutic expertise across oncology, rare diseases, and infectious diseases. Closely comparable to Farmacon in scale, regional specialization, and biotech/mid-pharma client mix.
• Veristat: Specialty CRO focused on complex clinical trials in rare diseases, oncology, and immunology for emerging biotech. Comparable therapeutic-area focus, sponsor profile (small/mid-biotech), and concierge-style service model targeting complex trials.
• Worldwide Clinical Trials: Mid-size specialty CRO with deep rare disease and central nervous system therapeutic expertise. Comparable to Farmacon in therapeutic-area specialization, mid-size scale, and focus on complex trials requiring scientific/medical leadership rather than pure scale.
• CTI Clinical Trial & Consulting Services: Specialty CRO with strong rare disease and oncology focus, comparable in therapeutic specialization and mid-size scale. CTI's hematology/oncology depth parallels Farmacon's rare disease and oncology expertise for biotech and mid-pharma sponsors.
• Ergomed (now PrimeVigilance): Specialty CRO with strong rare disease and oncology focus, acquired by Asahi Kasei. Comparable therapeutic specialization, integrated pharmacovigilance, and focus on complex small/mid-biotech sponsor relationships similar to Farmacon's biotech client base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/farmaconglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmacon Global